ATE228500T1 - Npy antagonisten - Google Patents

Npy antagonisten

Info

Publication number
ATE228500T1
ATE228500T1 AT98945708T AT98945708T ATE228500T1 AT E228500 T1 ATE228500 T1 AT E228500T1 AT 98945708 T AT98945708 T AT 98945708T AT 98945708 T AT98945708 T AT 98945708T AT E228500 T1 ATE228500 T1 AT E228500T1
Authority
AT
Austria
Prior art keywords
npy antagonists
npy
antagonists
Prior art date
Application number
AT98945708T
Other languages
English (en)
Inventor
Nils-Ake Bergman
Ambra Thomas D
Garry Pilling
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE228500T1 publication Critical patent/ATE228500T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT98945708T 1997-09-23 1998-09-21 Npy antagonisten ATE228500T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds
PCT/SE1998/001686 WO1999015498A1 (en) 1997-09-23 1998-09-21 New npy antagonists

Publications (1)

Publication Number Publication Date
ATE228500T1 true ATE228500T1 (de) 2002-12-15

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945708T ATE228500T1 (de) 1997-09-23 1998-09-21 Npy antagonisten

Country Status (21)

Country Link
US (1) US6127414A (de)
EP (1) EP1017672B1 (de)
JP (1) JP2001517651A (de)
KR (1) KR20010024220A (de)
CN (1) CN1279666A (de)
AR (1) AR017138A1 (de)
AT (1) ATE228500T1 (de)
AU (1) AU9288998A (de)
BR (1) BR9812492A (de)
CA (1) CA2303528A1 (de)
DE (1) DE69809782T2 (de)
EE (1) EE200000171A (de)
IL (1) IL134993A0 (de)
IS (1) IS5410A (de)
NO (1) NO20001483L (de)
PL (1) PL339617A1 (de)
SE (1) SE9703414D0 (de)
SK (1) SK3602000A3 (de)
TR (1) TR200000785T2 (de)
WO (1) WO1999015498A1 (de)
ZA (1) ZA988353B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (de) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH N-Guanidinoalkylamide, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen, die sie enthalten
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
JP4010951B2 (ja) * 2001-05-15 2007-11-21 大正製薬株式会社 アルギニン誘導体
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
JP2007509898A (ja) 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (de) 2006-11-30 2012-04-18 Probiodrug AG Neue inhibitoren von glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
JP2025540658A (ja) * 2022-11-23 2025-12-16 ラディオネティクス オンコロジー，インク． 神経ペプチドｙ１受容体（ｎｐｙ１ｒ）を標的とした治療薬およびその使用
TW202535356A (zh) * 2023-12-28 2025-09-16 美商萊迪奧尼提斯腫瘤醫學公司 神經肽y1受體(npy1r)靶向治療劑及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2242579A1 (en) * 1996-01-09 1997-07-17 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
US6011039A (en) * 1996-03-21 2000-01-04 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
EP1007073A4 (de) * 1996-06-04 2002-03-27 Synaptic Pharma Corp Verfahren zur änderung der essgewohnheiten, für diese verfahren geeignete verbindungen, sowie eine für einen hypothalamisches atypisches neuropeptid y/ peptide yy rezeptor kodierende dna
ATE230403T1 (de) * 1996-07-23 2003-01-15 Neurogen Corp Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
CA2260982A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
DE69721541T2 (de) * 1996-07-23 2004-03-18 Neurogen Corp., Branford Einige amido-und amino-substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifischen liganden
EP0984778B1 (de) * 1996-08-23 2002-06-12 Agouron Pharmaceuticals, Inc. Liganden des neuropeptids y
AU5135998A (en) * 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
WO1998025907A1 (en) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
CA2274593A1 (en) * 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
CA2274594C (en) * 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
JP2002514199A (ja) * 1997-02-04 2002-05-14 ブリストル−マイヤーズ スクイブ カンパニー Ｎｐｙ拮抗剤としてのジヒドロピリミドン誘導体
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
AU6309698A (en) * 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
CN1279666A (zh) 2001-01-10
IL134993A0 (en) 2001-05-20
CA2303528A1 (en) 1999-04-01
BR9812492A (pt) 2000-09-26
EP1017672A1 (de) 2000-07-12
NO20001483D0 (no) 2000-03-22
EP1017672B1 (de) 2002-11-27
AR017138A1 (es) 2001-08-22
DE69809782T2 (de) 2003-07-17
SK3602000A3 (en) 2001-01-18
SE9703414D0 (sv) 1997-09-23
IS5410A (is) 2000-03-20
US6127414A (en) 2000-10-03
KR20010024220A (ko) 2001-03-26
ZA988353B (en) 1999-03-23
NO20001483L (no) 2000-05-23
JP2001517651A (ja) 2001-10-09
WO1999015498A1 (en) 1999-04-01
EE200000171A (et) 2001-04-16
TR200000785T2 (tr) 2000-09-21
PL339617A1 (en) 2001-01-02
DE69809782D1 (de) 2003-01-09
AU9288998A (en) 1999-04-12

Similar Documents

Publication Publication Date Title
EP0986385A4 (de) Antagonisten des gonadorelins
DE69809782D1 (de) Npy antagonisten
ATE233260T1 (de) Muscarin-antagonisten
DK0973746T3 (da) Substituerede 3-cyanoquinoliner
ATA93198A (de) Fluoxetinpellets
DK1137493T3 (da) Forkompressionssystem
NO20000542L (no) Endothelin-antagonister
DE69818447D1 (de) Verbesserungen bezüglich der bilderzeugung
DE59813487D1 (de) Substituierte 4-benzoyl-pyrazole
ATA111897A (de) Kimme
NO20002555D0 (no) Skjøt
ATE236897T1 (de) 3-benzylpiperidine
NO305410B1 (no) B°lgekraftverk
ATA112597A (de) Snowboard - bindung
DK0960100T3 (da) Substituerede 4-benzoyl-pyrazoler
DE59807877D1 (de) Substituierte 4-benzoyl-pyrazole
ID24079A (id) Aminoheteroksiklilamida tersubstitusi
ATA65497A (de) Bauelement
ATA46498A (de) Kunststoffgleitbahn
ATA86797A (de) Verschleissschuh
DE59810960D1 (de) Substituierte phenyluracile
DE69708044D1 (de) Konstruktionsteil
KR980001295U (ko) 개량 도장
ATE266645T1 (de) Substituierte phenyluracile
SK2042U (sk) Balkón

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties